利多卡因对开胸犬除动脉值和脆弱性上限之间的关系的影响
S L Topham1, Y M Cha, B B Peters
1Department of Medicine, University of California San Diego Medical Center 92103-8411.
Circulation
|March 1, 1992
概括
利多卡因增加了狗的除门 (DFT50) 和脆弱性的上限 (ULV50). 然而,ULV50的增加超过了DFT50,这表明其他因素影响了除.
科学领域:
- 心血管生理学心血管生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 除门和脆弱性上限之间的关系对于理解除功效至关重要.
- 利多卡因是一种抗失律药物,已知对心脏电生理学有影响.
研究的目的:
- 调查利多卡因对除门 (DFT50) 和脆弱性上限 (ULV50) 的影响.
主要方法:
- 开放胸部的狗被用于在输注利多卡因之前和期间确定DFT50和ULV50.
- 采用了延迟上下方法和补丁电极配置.
- 血清里多卡因水平和心电图参数 (QT 间隔,QRS 综合体) 被监测.
主要成果:
- 利多卡因在狗中显著增加了ULV50和DFT50.
- 在输注利多卡因期间,ULV50的增加大于DFT50.
- 正常的盐水输液没有影响ULV50或DFT50.0.
结论:
- 利多卡因的使用提高了脆弱性的上限和除门.
- 这些发现支持了除的脆弱性假设的上限.
- ULV50的不成比例增加表明,在利多卡因治疗期间,其他因素影响了除的结果.
相关概念视频
Pathophysiology of Cardiac Performance
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...


